Health officials are screening people who were exposed and monitoring the sick patient's treatment.
The latest Global Tuberculosis Report shows an increase in the number of people diagnosed with TB, which means more patients are getting the treatment and services they need.
The authors say the study underscores the importance of adequate drug-susceptibility testing capacity.
The decision means generic versions of the drug, which is a critical part of shorter regimens for drug-resistant TB, can be made and sold in 134 low- and middle-income countries.
Although progress has stalled, world leaders at today's UN high-level meeting will commit to new targets aimed at reducing TB incidence and deaths.
The deal is expected to make 5 million more tests available, improving access for lower- and middle-income countries.
The authors said the case report provides a cautionary example for health providers in areas with low TB incidence.
The price cut for bedaquiline will enable low- and middle-income countries to buy more WHO-recommended treatment regimens for drug-resistant TB.
EU countries reported 33,527 TB cases in 2021, which continues a downward trend observed since 2002.
Scaling up preventive TB treatment for people with HIV/AIDS and household contacts of newly diagnosed TB patients could save nearly 850,000 lives by 2035, experts estimate.
